Stockholm, Sweden based Pharmadule builds pharmaceutical plants using a modular approach in which each section of a design is made separately before being combined to form the final facility.
Under the new deal Morimatsu will make the modules at its plant in Shanghai by Q2 this year. Pharamdule CEO Lars Martinsson told in-PharmaTechnologist that the accord is an important move for the firm.
“We see a huge potential in the fast growing Chinese market with great investment programs, and therefore a strong interest in Pharmadule's modular concept.”
Martinsson also said that Pharmadule’s presence in China is already attracting interest from Big Pharma and added that: “Discussions regarding future projects are in an advanced stage with multiple companies.”
Despite being headquartered in Japan Morimatsu has operated in China for 20 years as a producer of manufacturing equipment and tanks for the countries’ pharmaceutical, cosmetic and food manufacturing industries.
This established presence and manufacturing infrastructure is important for Pharmadule’s entry into the market according to Martinsson, who said that the partnership will “enable a fast and smooth start up of the production.”
Pharmdule’s modular approach, which it claims is “fastest and most profitable way to implement a pharmaceutical or biopharmaceutical production facility,” suits the rapidly expanding drug manufacturing industry in China.
For example, the ability to set up a facility that is pre-validated to good manufacturing practice (GMP) standards in as little as 12 months is likely to win custom from Chinese drugmakers hoping to target lucrative international markets.